| Literature DB >> 29057832 |
Baldomero Esquivel1, Celia Bustos-Brito2, Mariano Sánchez-Castellanos3, Antonio Nieto-Camacho4, Teresa Ramírez-Apan5, Pedro Joseph-Nathan6, Leovigildo Quijano7.
Abstract
From the aerial parts of Salvia ballotiflora, eleven diterpenoids were isolated; among them, four icetexanes and one abietane (1-5) are reported for the first time. Their structures were established by spectroscopic means, mainly ¹H- and 13C-NMR, including 1D and 2D homo- and hetero-nuclear experiments. Most of the isolated diterpenoids were tested for their antiproliferative, anti-inflammatory, and radical scavenging activities using the sulforhodamine B assay on six cancer cell lines, the TPA-induced ear edema test in mice, and the reduction of the DPPH assay, respectively. Some diterpenoids showed anti-proliferative activity, these being icetexanes 6 and 3, which were the most active with IC50 (μM) = 0.27 ± 0.08 and 1.40 ± 0.03, respectively, for U251 (human glioblastoma) and IC50 (μM) = 0.0.46 ± 0.05 and 0.82 ± 0.06 for SKLU-1 (human lung adenocarcinoma), when compared with adriamycin (IC50 (μM) = 0.08 ± 0.003 and 0.05 ± 0.003, as the positive control), respectively. Compounds 3 and 10 showed significant reduction of the induced ear edema of 37.4 ± 2.8 and 25.4 ± 3.0% (at 1.0 μmol/ear), respectively. Compound 4 was the sole active diterpenoid in the antioxidant assay (IC50 = 98. 4 ± 3.3), using α-tocopherol as the positive control (IC50 (μM) = 31.7 ± 1.04). The diterpenoid profile found is of chemotaxonomic relevance and reinforces the evolutionary link of S. ballotiflora with other members of the section Tomentellae.Entities:
Keywords: Salvia ballotiflora; VCD analyses; abietane diterpenoids; anti-inflammatory activity; antiproliferative activity; icetexane diterpenoids; radical scavenger capacity
Mesh:
Substances:
Year: 2017 PMID: 29057832 PMCID: PMC6151488 DOI: 10.3390/molecules22101690
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of 1–11.
NMR data (1H 700 MHz, 13C 175 MHz, CDCl3) of 1 and 2.
| 1 | 2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Position | δC | Type | δH ( | HMBC | δC | Type | δH ( | HMBC |
| 1 | 68.2 | CH | 4.73, brt (7.7) | 3, 5, 10, 20 | 66.6 | CH | 4.57, t (2.9) | 3, 5, 20 |
| 2a | 29.0 | CH2 | 2.49, ddt (13.3, 10.5, 8.4) | 3, 4, 10 | 28.1 | CH2 | 2.01, dq (14.7, 3.5) | 1, 4, 10 |
| 2b | 1.69, dtd (13.4, 8.2, 2.4) | 1.41, dddd (14.7, 11.9, 5.6, 2.8) | 3 | |||||
| 3a | 26.8 | CH2 | 1.81, m | 1, 2, 4, 5, 18 | 25.5 | CH2 | 2.18, m | 1, 2, 4, 19 |
| 3b | 2.16, m | 1, 2, 4, 19 | ||||||
| 4 | 44.4 | C | 42.7 | C | ||||
| 5 | 44.1 | CH | 3.41, d (10.2) | 3, 4, 6, 7, 10, 18, 20 | 44.8 | CH | 2.85, brs | 1, 4, 10, 9, 18, 19, 20 |
| 6 | 79.9 | CH | 4.29, dd (10.3, 2.3) | 5, 7, 10 | 130.2 | C | ||
| 7 | 65.0 | CH | 5.53, brs | 6, 8, 9 | 100.5 | CH | 6.77, d (1.1) | 5, 6, 9, 4 |
| 8 | 132.2 | C | 140.0 | C | ||||
| 9 | 137.7 | C | 149.9 | C | ||||
| 10 | 153.1 | C | 138.0 | C | ||||
| 11 | 184.3 | C | 182.8 | C | ||||
| 12 | 150.3 | C | 151.2 | C | ||||
| 13 | 126.8 | C | 126.5 | C | ||||
| 14 | 187.3 | C | 185.3 | C | ||||
| 15 | 24.7 | CH | 3.25, hept (7.1) | 12, 13, 14, 16, 17 | 24.8 | CH | 3.28, hept (7.1) | 12, 13, 14, 16, 17 |
| 16, 17 | 19.9, 20.0 | 2CH3 | 1.26, d (7.1) | 13, 15 | 20.0, 20.1 | 2CH3 | 1.27, 1.26, d (7.1) | 13, 15 |
| 18 | 22.7 | CH3 | 1.47, s | 3, 4, 5, 19 | 27.5 | CH3 | 1.44, s | 3, 4, 5, 19 |
| 19 | 179.8 | C | 179.3 | C | ||||
| 20 | 112.3 | CH | 7.07, t (2.5) | 1, 5, 6, 9, 11 | 122.8 | CH | 6.91, d (1.82) | 1, 5, 8, 9, 11 |
| 1-OH | 1.97, brs | |||||||
| 7-OH | 3.11, d (4.33) | |||||||
| 12-OH | 7.14, brs | 12, 13, 11 | ||||||
Figure 2Selected correlations for compound 1.
Figure 3Selected correlations for compound 2.
NMR data (1H 700 MHz, 13C 175 MHz, CDCl3) of 3.
| 3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Position | δC | Type | δH ( | HMBC | Position | δC | Type | δH ( | HMBC |
| 1a | 37.4 | CH2 | 1.98, dd (12.6, 4.9) | 3, 5, 10, 20 | 11 | 183.5 | C | ||
| 1b | 1.77, d (12.0, 5.4) | 3, 5 | 12 | 150.4 | C | ||||
| 2a | 20.0 | CH2 | 1.84, m | 3, 4, 10 | 13 | 125.6 | C | ||
| 2b | 1.65, m | 3, 4 | 14 | 184.3 | C | ||||
| 3a | 35.5 | CH2 | 1.73, m | 1, 5 | 15 | 24.7 | CH | 3.21, hept (7.0) | 12, 13, 14, 16, 17 |
| 3b | 1.66, dd (12.9, 6.1) | 5 | 16, 17 | 19.9, 19.8 | 2CH3 | 1.24, 1.27, d (7.0) | 13, 15 | ||
| 4 | 49.6 | C | 18 | 17.2 | CH3 | 1.11, s | 3, 4, 19 | ||
| 5 | 51.0 | CH | 2.37, dd (12.0, 5.4) | 3, 4, 6, 19 | 19 | 179.6 | C | ||
| 6a | 27.2 | CH2 | 2.27, ddd (15.0, 7.2, 5.5) | 5, 7, 8, 10 | 20a | 30.2 | CH2 | 3.43, d (15.7) | 1, 5, 8, 9, 10, 11 |
| 6b | 1.43, brdd (15.0, 12.0) | 5, 10, 8 | 20b | 3.01, d (15.7) | 5, 8, 9, 10, 11 | ||||
| 7 | 65.9 | CH2 | 6.21, d (7.0) | 1′, 5, 6, 8, 9, 14 | 1′ | 169.6 | C | ||
| 8 | 144.4 | C | 2′ | 20.7 | CH3 | 2.09, s | 1′ | ||
| 9 | 135.4 | C | 11-OH | ||||||
| 10 | 81.8 | C | 12-OH | 7.01, brs | 12, 13, 11 | ||||
Figure 4Selected correlations for compound 3.
Figure 5Experimental and Density functional theory (DFT) calculated, at the B3PW91/DGDZVP level of theory, IR, and VCD spectra of 7α-acetoxy-6,7-dihydroicetexone (3, (A)), anastomosine (6, (B)), and 7,20-dihydroanastomosine (7, (C)).
Confidence level data for the IR and VCD spectra of 3, 6, and 7.
| Compound | ||||||
|---|---|---|---|---|---|---|
| 0.973 | 95.6 | 79.7 | 13.1 | 66.6 | 100 | |
| 0.975 | 82.4 | 87.0 | 4.2 | 82.8 | 100 | |
| 0.974 | 93.2 | 84.7 | 10.9 | 73.8 | 100 |
a Anharmonicity factor; b IR spectral similarity; c VCD spectral similarity for the correct enantiomer; d VCD spectral similarity for the incorrect enantiomer; e Enantiomer similarity index, calculated as SE–S-E; and f Confidence level for the stereochemical assignment.
Relative energies and conformational populations of 3, 6, and 7.
| Conformer | Δ | %MMFF94 b | Δ | %OPT | Δ | %B3PW91 |
|---|---|---|---|---|---|---|
| 0.88 | 16.3 | 0.00 | 36.9 | 0.00 | 50.8 | |
| 0.00 | 72.6 | 0.08 | 32.0 | 0.34 | 28.4 | |
| 1.22 | 9.3 | 0.37 | 19.6 | 0.67 | 16.5 | |
| 2.37 | 1.3 | 0.84 | 9.1 | 1.46 | 4.3 | |
| 0.87 | 18.8 | 0.00 | 56.2 | 0.00 | 69.2 | |
| 0.00 | 81.2 | 0.15 | 43.8 | 0.48 | 30.8 | |
| 0.81 | 20.1 | 0.00 | 58.4 | 0.00 | 65.5 | |
| 0.00 | 79.9 | 0.20 | 41.6 | 0.06 | 34.5 |
a Molecular mechanics energy relative to 33.25, 44.21 and 64.23 kcal/mol for 3, 6 and 7, respectively; b Molecular mechanics population in percent; c Energy of the optimized structures; data are relative to −866,097.07 kcal/mol for 3, −721,603.93 kcal/mol for 6, and −722,370.35 kcal/mol for 7; d Free energy relative to −7,865,847.05 kcal/mol for 3, −721,405.65 kcal/mol for 6, and −722,157.46 kcal/mol for 7.
NMR data (1H 700 MHz, 13C 175 MHz, CDCl3) of 4.
| 4 | ||||
|---|---|---|---|---|
| Position | δC | Type | δH ( | HMBC |
| 1a | 35.9 | CH2 | 2.07, dd (13.4, 5.6) | 1, 2, 4, 5, 18 |
| 1b | 1.71, ddd (13.4, 10.8, 7.6) | 1, 2, 4, 5, 19 | ||
| 2a | 19.5 | CH2 | 1.82, m | 1, 3, 4 |
| 2b | ||||
| 3a | 32.7 | CH2 | 1.76, m | 2, 3, 5, 20 |
| 3b | 1.53, ddd (12.8, 12.6, 7.6) | 2, 5 | ||
| 4 | 47.7 | C | ||
| 5 | 50.9 | CH | 2.00, dd (12.0, 2.0) | 1, 3, 4, 6, 7, 19 |
| 6a | 40.6 | CH2 | 2.84, dd (17.4, 12.0) | 4, 5, 7, 10 |
| 6b | 2.80, dd (17.4, 2.0) | 4, 5, 7, 8, 10 | ||
| 7 | 204.8 | C | ||
| 8 | 113.1 | C | ||
| 9 | 120.0 | C | ||
| 10 | 85.2 | C | ||
| 11 | 134.9 | C | ||
| 12 | 150.3 | C | ||
| 13 | 119.9 | C | ||
| 14 | 159.2 | C | ||
| 15 | 24.8 | CH | 3.46, hept (7.0) | 12, 13, 14, 16, 17 |
| 16, 17 | 20.47, 20.51 | CH3 | 1.37, 1.36, d (7.0) | 13, 15 |
| 18 | 17.1 | CH3 | 1.18, s | 3,4, 5, 19 |
| 19 | 179.1 | CH3 | ||
| 20a | 33.6 | CH2 | 3.59, d (13.9) | 1, 5, 8, 9, 10, 11 |
| 20b | 2.95, d (13.9) | 1, 8, 9, 10, 11 | ||
| 1′ | ||||
| 2′ | ||||
| 11-OH | 6.13, s | 9, 11, 12, 13 | ||
| 12-OH | 4.86, s | 9, 11, 12, 13 | ||
| 14-OH | 13.00, s | 8, 9, 12, 13, 14, 7 | ||
Figure 6Selected correlations for compound 4.
NMR data (1H 700 MHz, 13C 175 MHz, CDCl3) of 5.
| 5 | ||||
|---|---|---|---|---|
| Position | δC | Type | δH ( | HMBC |
| 1a | 36.2 | CH2 | 3.17, dd (13.2, 2.8) | 1, 3, 5 |
| 1b | 1.55, dd (13.6, 3.7) | 2, 20 | ||
| 2a | 18.4 | CH2 | 1.82, dddd (17.3, 13.7, 8.7, 3.7) | 4, 10 |
| 2b | 1.68, ddt (14.2, 7.2, 3.6) | 4, 10 | ||
| 3a | 35.1 | CH2 | 1.50, td (13.6, 3.7) | 19 |
| 3b | 1.41, dt (14.0, 2.7) | 1, 5 | ||
| 4 | 36.9 | C | ||
| 5 | 44.2 | CH | 2.22, dd (11.9, 5.5) | 1, 7, 10, 18, 19 |
| 6a | 35.4 | CH2 | 2.58, d (17.0) | 4, 5, 8, 10 |
| 6b | 2.55, d (17.0) | 4, 5, 8, 10 | ||
| 7 | 198.2 | C | ||
| 8 | 125.4 | C | ||
| 9 | 138.3 | C | ||
| 10 | 40.1 | C | ||
| 11 | 141.3 | C | ||
| 12 | 146.2 | C | ||
| 13 | 131.8 | C | ||
| 14 | 118.1 | CH | 7.64, s | |
| 15 | 27.5 | CH | 3.01, hept (6.9) | 12, 13, 14, 16, 17 |
| 16, 17 | 22.5, 22.6 | CH3 | 1.30, 1.28, d (6.86) | 13, 15 |
| 18 | 17.7 | CH3 | 0.99, s | 3, 4, 5, 19 |
| 19a | 72.0 | C | 3.84, d (11.3) | 3, 5, 18, 1′ |
| 19b | 3.73, d (11.3) | 3, 5, 18, 14 | ||
| 20a | 19.2 | CH3 | 1.43, s | 1, 5, 9, 10 |
| 20b | ||||
| 11-OH | 5.70, s | 11 | ||
| 12-OH | 5.61, s | 11, 12 | ||
| 1′ | 171.3 | C | ||
| 2′ | 21.1 | CH3 | 2.02, s | 1′, 19 |
Figure 7Selected correlations for compound 5.
Figure 8PLUTO plots of the single crystal X-ray diffraction structures of anastomosine (6, top) and of 7,20-dihydroanastomosine (7, bottom).
IC50 (μM) values of antiproliferative activity for compounds 3, 6, 7, and 8.
| Compound | IC50 (μM) (SI) | ||||
|---|---|---|---|---|---|
| U251 | SKLU-1 | COS-7 | K562 | MCF-7 | |
| 1.4 ± 0.03 (1.2) | 0.82 ± 0.06 (2.0) | 1.62 ± 0.1 | Nd | Nd | |
| 0.27 ± 0.08 (2.3) | 0.46 ± 0.05 (1.3) | 0.61 ± 0.007 | Nd | Nd | |
| Nd | Nd | Nd | 31.2 ± 1.1 | 33.24 ± 1.2 | |
| Nd | Nd | Nd | 17.0 ± 1.4 | 28.7 ± 1.6 | |
| Adriamicyn | 0.08 ± 0.003 (3.1) | 0.05 ± 0.003 (5.0) | 0.25 ± 0.009 | 0.20 ± 0.02 | 0.23 ± 0.02 |
Results represent the mean ± SD of at least three different experiments; Nd = Not determined; U251 = human glioblastoma; SKLU-1 = human lung adenocarcinoma; K562 = human chronic myelogenous leukemia; MCF-7 = human mammary adenocarcinoma; COS-7 normal monkey kidney; SI = selectivity index calculated as the quotient of IC50 of COS-7/ IC50 of cancer cell lines. For compounds 3 and 6, IC50 was determined at four concentrations in a range of 1.0 to 0.18 μM; 75.0 to 12.5 μM for 7, and 50.0 to 6.25 μM for 8.
Inhibitory effect of compounds 3, 6, 7 and 10 on TPA-induced inflammation in a mouse model.
| Compound | Edema (mg) | Inhibition of Edema (%) |
|---|---|---|
| Control (TPA) | 15.77 ± 0.78 | |
| 9.87 ± 0.44 ** | 37.42 ± 2.77 ** | |
| 15.97 ± 0.61 | NA | |
| 15.50 ± 0.76 | NA | |
| 11.77 ± 047 ** | 25.37 ± 2.98 ** | |
| Indometacin | 2.88 ± 0.73 ** | 78.76 ± 7.68 ** |
| Celecoxib | 6.94 ± 1.56 * | 54.34 ± 10.28 |
Effects on ear edema of female mice CD-1; Doses (1.0 μmol ear−1); each value represents the mean of three–seven animals ± SEM; The results were analyzed with the Dunnett test; The values at p ≤ 0.05 (*) and p ≤ 0.01 (**) were considered as significant differences with respect to the control group. NA = Non-active.
Figure 9Dose-response curve for determining the IC50 value for scavenging activity on free radical 2,2-diphenil-1-picrylhydrazyl (DPPH) of compound 4 compared with standards α-tocopherol and quercetin. Values represent the mean of at least three independent experiments ± SEM, * p ≤ 0.05, ** p ≤ 0.01 indicate significant differences when compared with the control group (two-way ANOVA followed by the Dunnett post-test).